BrightHeart banks €11M to reimagine prenatal care with AI
European femtech startup BrightHeart has raised €11 million in fresh funding to develop AI-powered prenatal screening tools, betting that smarter software can spot risks in pregnancy earlier, more accurately, and at a fraction of current costs. The round underscores growing investor conviction that artificial intelligence will play a central role in the next generation of maternal health and fetal monitoring.
Why prenatal care is ripe for AI disruption
Prenatal care is still heavily dependent on the availability and skill of trained specialists. Expectant parents typically rely on a small pool of obstetricians, sonographers, and fetal medicine experts to interpret complex ultrasound images and other diagnostics. In many regions, particularly outside major cities, that expertise is scarce, leading to delayed or missed diagnoses.
Meanwhile, the volume of data generated during pregnancy is rising. High-resolution ultrasound, Doppler imaging, non-invasive prenatal testing (NIPT), and continuous vital sign monitoring can produce rich clinical information that often goes underused due to time and staffing constraints.
This is where AI algorithms are increasingly seen as transformative. Properly trained on large, high-quality datasets, they can assist clinicians in:
- Detecting subtle anomalies in fetal development that are easy for the human eye to miss
- Standardising assessments across clinics and countries
- Triaging high-risk pregnancies earlier for specialist review
- Reducing false positives that trigger unnecessary anxiety and follow-up tests
BrightHeart is positioning itself at the intersection of these needs, aiming to turn complex imaging and clinical data into clear, actionable risk assessments throughout pregnancy.
What BrightHeart is building
While the company is still early in its commercial journey, BrightHeart is understood to be developing a software platform that can integrate with existing ultrasound systems and electronic health records. Its core offering is an AI-based decision-support layer that runs in the background as clinicians perform standard scans.
The platform’s objectives include:
- Analysing ultrasound images in real time to highlight potential structural or growth-related abnormalities
- Combining imaging data with maternal history, lab results, and vital signs to generate a dynamic risk score
- Providing evidence-based recommendations for follow-up imaging, specialist referral, or additional testing
- Creating a longitudinal view of the pregnancy, tracking changes over time rather than treating each visit in isolation
In practical terms, that means a clinician conducting a routine scan could receive on-screen prompts if the AI detects a pattern associated with preeclampsia, fetal growth restriction, or specific congenital anomalies. The goal is not to replace the clinician but to act as a second set of expert eyes, particularly valuable in clinics that lack subspecialist support.
How the €11M funding will be used
The new €11 million injection gives BrightHeart the runway to move from technical validation toward clinical deployment. The company is expected to focus on three main areas:
1. Clinical validation and regulatory approvals
For any medical device software, rigorous validation is non-negotiable. BrightHeart will need to run extensive clinical studies to demonstrate that its AI models are accurate, reliable, and safe across diverse populations, and not just on the datasets used for training.
The company will also need to navigate complex regulatory pathways, securing approvals such as CE marking in Europe and, potentially in time, FDA clearance in the United States. That process typically requires robust evidence that the technology improves outcomes or efficiency without compromising patient safety.
2. Product development and integration
Beyond the algorithms themselves, BrightHeart must ensure its tools fit seamlessly into clinical workflows. That means investing in user experience design, interoperability with existing hospital information systems, and compatibility with major ultrasound hardware vendors.
Hospitals and clinics are wary of tools that slow down appointments or require extensive retraining. To gain adoption, the platform will need to be intuitive, fast, and easily configurable to local protocols.
3. International expansion and partnerships
Given that prenatal care challenges are global, BrightHeart is likely to target both high-income and emerging markets. In well-resourced health systems, the pitch will emphasise improved accuracy, reduced workload, and better documentation. In lower-resource settings, the promise is more fundamental: bringing specialist-level screening capabilities to regions where such expertise is scarce or absent.
Strategic partnerships with hospital networks, telemedicine platforms, and public health agencies will be critical to scale. The new funding gives the company leverage to negotiate pilots and long-term collaborations.
The broader AI-in-healthcare trend
BrightHeart is part of a wider wave of startups applying machine learning to medical imaging and diagnostics. From oncology and cardiology to ophthalmology, AI decision-support systems are moving from research labs into everyday clinical practice.
However, prenatal care presents unique sensitivities. Misdiagnosis can have profound emotional and ethical implications for families, and clinicians remain cautious about overreliance on automated tools. As a result, companies in this space must prioritise:
- Transparency in how models reach their conclusions
- Bias mitigation to ensure performance across ethnicities and geographies
- Data privacy and secure handling of imaging and genetic information
- Clear delineation of responsibility between human clinicians and AI systems
Regulators and professional bodies are increasingly issuing guidance on the safe use of AI in clinical practice, and companies like BrightHeart will need to align closely with these evolving standards.
What this means for expectant parents and clinicians
If BrightHeart delivers on its ambitions, the impact for expectant parents could be significant. Earlier and more precise detection of complications can open the door to timely interventions, better birth planning, and improved long-term outcomes for both mother and child. For clinicians, AI-assisted tools may help manage growing workloads, standardise care across regions, and reduce the cognitive burden of interpreting ever more complex data.
For now, the €11 million round is a vote of confidence that AI-driven prenatal care is moving from concept to reality. The next few years will show whether BrightHeart can convert technical promise into measurable improvements in maternal and fetal health around the world.